CareDx Announces Third Quarter 2026 Financial Results
CareDx reported Q3 2026 revenue of $139 million, up 39% year-over-year, with Testing Services revenue up 65% to $119 million and volume of roughly 75,900 tests. GAAP net income was $19 million versus $2 million a year ago, with diluted EPS of $0.35, and Adjusted EBITDA doubled to $30 million on a 22% margin. The company raised FY2026 guidance to $520-$530 million in revenue (from $490-$500 million) and $90-$100 million in Adjusted EBITDA (from $66-$78 million).
Key figures
- Eps
- 0.35
- Revenue
- 139362000
- Guidance
- FY2026 revenue $520M-$530M (raised from $490M-$500M); Adjusted EBITDA $90M-$100M (raised from $66M-$78M)
- Revenue Yoy
- 39%
- Fcf
- 11103000
- Adjusted ebitda
- 30496000
- Gaap net income
- 19292000
- Gross margin gaap
- 71%
- Testing volume yoy
- 51%
- Operating cash flow
- 12718000
- Cash and equivalents
- 250480000
- Non gaaap net income
- 38368000
- Non gaap diluted eps
- 0.7
- Gross margin non gaap
- 74%
- Adjusted ebitda margin
- 22%
- Testing services volume
- 75900
- Testing services revenue
- 119191000
- Testing services revenue yoy
- 65%
- Patient digital solutions revenue
- 20171000
- Patient digital solutions revenue yoy
- 31%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.